


Diagnostic, Correlative & Epidemiologic

****SUSPENDED** UCI 08-70**
Establishment of a Multidisciplinary Pancreatic Tumor Biorepository and Integrated Clinical Database (Demirjian)



Adenocarcinoma
Stage IV Metastatic

1st LINE

UCI 15-94
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma (Seery)

Adjuvant Treatment

ROTOG 0848
A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients w/ Resected Head of Pancreas Adenocarcinoma (Seery)

ALLIANCE A021501
Preoperative extended chemotherapy vs. chemotherapy plus hypo fractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas (Seery)




1st LINE

****SUSPENDED** SWOG 1313**
A Phase IB/II Randomized Study of Modified FOLFIRINOX + PEGPH20 versus Modified FOLFIRINOX Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma (Seery)

EAY131 (MATCH)
Molecular Analysis for Therapy Choice (Seery)

2nd LINE

UCI 14-71
A Phase III Randomized Study of Olaparib Monotherapy in gBRCA Mutated Metastatic Pancreatic Cancer (Seery)



Cholangio

UCI 16-64 A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations who Failed Previous Therapy (Seery)

UCI 17-49** A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with Cisplatin Plus Gemcitabine and PEGPH20 in Combination with Atezolizumab and Cisplatin Plus Gemcitabine Compared with Cisplatin Plus Gemcitabine in Hyaluronan-High (HA-high) Subjects with Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

UCI 17-39** A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH Mutation (Seery)